Leonard Frank X 4
4 · NovoCure Ltd · Filed Mar 3, 2026
Insider Transaction Report
Form 4
NovoCure LtdNVCR
Leonard Frank X
Chief Executive Officer
Transactions
- Sale
Ordinary Shares
[F1][F2]2026-02-27$13.66/sh−9,734$133,003→ 338,011 total - Award
Ordinary Shares
[F3]2026-02-28+18,621→ 356,632 total - Sale
Ordinary Shares
[F1][F4]2026-03-02$13.49/sh−7,232$97,581→ 349,400 total
Footnotes (4)
- [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.
- [F3]Represents vesting of performance-based restricted stock units.
- [F4]This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price.
Signature
Steven Robbins, as attorney in fact for Leonard, Frank X.|2026-03-03